ACTH antagonist CRN04894
Term · Oncology and biomedicine · MLC-T-ONC-009613
An orally bioavailable nonpeptide antagonist of the adrenocorticotropic hormone (ACTH) receptor (ACTHR; melanocortin receptor 2; MC2R), with potential steroid hormone production inhibitory activity. Upon oral administration, ACTH antagonist CRN04894 competes with ACTH for receptor binding to MC2R in the adrenal cortex and inhibits ACTH signaling. This may inhibit the synthesis and secretion of steroid hormones. MC2R, a member of the melanocortin receptor subfamily of type 1 G protein-coupled receptors, plays a key role in adrenal steroidogenesis.
| Identifier | MLC-T-ONC-009613 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | MC2R antagonist CRN04894 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009613",
"term": "ACTH antagonist CRN04894",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable nonpeptide antagonist of the adrenocorticotropic hormone (ACTH) receptor (ACTHR; melanocortin receptor 2; MC2R), with potential steroid hormone production inhibitory activity. Upon oral administration, ACTH antagonist CRN04894 competes with ACTH for receptor binding to MC2R in the adrenal cortex and inhibits ACTH signaling. This may inhibit the synthesis and secretion of steroid hormones. MC2R, a member of the melanocortin receptor subfamily of type 1 G protein-coupled receptors, plays a key role in adrenal steroidogenesis.",
"synonyms": [
"MC2R antagonist CRN04894"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/acth-antagonist-crn04894/"
}
Record 286 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.